Clinical trial · Interventional
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis-A Registry Project
NCT02456363CI-TRIAL-00018062unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ankylosing Spondylitis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NSAIDs and sulfasalazine | Drug | — | UNRESOLVED |
| TNF alpha | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- NSAIDs(+) and sulfasalazine(+)
- description
- use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
- interventionNames
- Biological: TNF alpha
- Drug: NSAIDs and sulfasalazine
- type
- EXPERIMENTAL
- label
- NSAIDs(+) and sulfasalazine(-)
- description
- use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
- interventionNames
- Biological: TNF alpha
- Drug: NSAIDs and sulfasalazine
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years old * HLA B27 positive * X ray examination * Clinical symptoms and physical examination, the following three conditions are subject to at least two: i.lower back pain and morning stiffness symptoms persist more than 3 months ii. lumbar activity is restricted iii. chest expansion is restricted * Active disease for four weeks or more (continue two examination BASDAI\>6, ESR\> 28 mm/1 hr and CRP\>1 mg/dl) Exclusion Criteria: * pregnant or breast-feeding women * patients with active infections * highly infectious patients * Cancer or precancerous condition of the patient * multiple sclerosis
References
Publications (0)
Data not yet available
No reference posted for this study.